Cardiol Therapeutics (CRDL) Stock Forecast & Price Target

Cardiol Therapeutics is viewed favorably because its peer-reviewed MAVERIC-Pilot data in 27 difficult-to-treat recurrent pericarditis patients showed rapid, durable symptom relief and a steep annualized event-rate decline from 5.8 to 0.9, alongside objective anti-inflammatory effects with mean CRP falling from 5.7 mg/dL to 0.3 mg/dL. The company’s oral, steroid-sparing CardiolRx could occupy a differentiated position before injectable IL-1 blockers or as a step-down maintenance option, especially since the population resembled higher-relapse cohorts and background-therapy withdrawal was often successful. While the ongoing randomized Phase III MAVERIC trial and 1Q27 readout remain the key catalysts, the published Phase II evidence and ARCHER myocarditis program support a favorable clinical and commercial risk-reward profile.

Cardiol Therapeutics is a development-stage company whose valuation depends heavily on clinical execution, yet its core MAVERIC trial has already been extended from 110 to up to 150 patients because the blinded recurrence rate is lower than expected, delaying topline results to mid-2027. That slower event accumulation creates uncertainty around the trial’s power and suggests the market must still discount meaningful clinical risk, especially because the business has only one principal late-stage asset in recurrent pericarditis while the myocarditis and heart failure programs remain assigned low probabilities of success. Although cash on hand is said to fund operations into 3Q27, the stock near $1 adds financing and delisting risk, leaving the fundamentals fragile despite the rNPV framework.